Rhumbline Advisers Buys 15,847 Shares of Natera, Inc. $NTRA

Rhumbline Advisers increased its stake in Natera, Inc. (NASDAQ:NTRA) by 10.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 169,249 shares of the medical research company’s stock after buying an additional 15,847 shares during the period. Rhumbline Advisers’ holdings in Natera were worth $28,593,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Journey Strategic Wealth LLC bought a new position in Natera in the 2nd quarter worth about $290,000. CFC Planning Co LLC purchased a new stake in shares of Natera in the second quarter valued at approximately $621,000. Franklin Resources Inc. grew its stake in Natera by 20.6% in the second quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock worth $327,346,000 after purchasing an additional 330,696 shares in the last quarter. Legal & General Group Plc grew its stake in Natera by 30.6% in the second quarter. Legal & General Group Plc now owns 331,287 shares of the medical research company’s stock worth $55,968,000 after purchasing an additional 77,547 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Natera by 44.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after purchasing an additional 3,263,822 shares during the period. Institutional investors own 99.90% of the company’s stock.

Insider Activity

In other news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total transaction of $499,860.00. Following the transaction, the insider directly owned 120,859 shares of the company’s stock, valued at approximately $20,137,526.58. This represents a 2.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roelof Botha sold 75,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $236.12, for a total value of $17,709,000.00. Following the sale, the director owned 1,154,198 shares of the company’s stock, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 308,366 shares of company stock worth $63,050,068. Insiders own 5.63% of the company’s stock.

Natera Price Performance

Shares of NTRA stock opened at $237.12 on Thursday. The stock’s 50-day moving average is $190.07 and its 200 day moving average is $169.57. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $241.28. The company has a market cap of $32.72 billion, a P/E ratio of -103.55 and a beta of 1.75.

Natera (NASDAQ:NTRA) last announced its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The firm had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. The business’s revenue for the quarter was up 34.7% compared to the same quarter last year. On average, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on NTRA shares. JPMorgan Chase & Co. upped their target price on Natera from $240.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday. Stephens raised their price target on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Morgan Stanley increased their target price on shares of Natera from $195.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Finally, BNP Paribas Exane upgraded shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price target for the company in a report on Monday, October 27th. Fifteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $220.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.